Product Description
Triflurane was developed by Sanofi Aventis under the trade name Aubagio. And on September 12, 2012, the FDA approved the treatment of relapsing multiple sclerosis drugs. The drug is an immunomodulator that blocks the synthesis of pyrimidine by inhibiting dihydroorotate dehydrogenase. Triflurane is an in vivo active metabolite of leflunomide. (Sourced from: https://www.fluoropharm.com/news/1033.html)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|